Curated news and analysis on clinical trials, drug approvals, and medical research.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
Novartis AG sells 70.7% stake in its Indian unit to a private equity consortium led by WaveRise Investments for $159 million, marking a complete exit from the listed subsidiary while retaining its commercial operations.
The National Security Commission on Emerging Biotechnology toured Pittsburgh's advanced research facilities, including Carnegie Mellon's AI Science Foundry and the University of Pittsburgh's BioForge building, as part of a nationwide biotechnology hub assessment.
Novartis AG sells its entire 70.68% stake in Novartis India Ltd. for $159 million to a consortium of investors, concluding a two-year strategic review while maintaining operations through its wholly-owned Indian subsidiary.
Grail's multi-cancer blood test failed to significantly boost early detection or reduce late-stage diagnoses in a 142,000-person UK trial, raising doubts about regulatory approval and commercial prospects.
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
The FDA has accepted Teva Pharmaceutical's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine extended-release injectable suspension for treating schizophrenia in adults, supported by Phase 3 SOLARIS trial data.
BioNTech filed a patent infringement lawsuit against Moderna in Delaware federal court, alleging that Moderna's next-generation COVID-19 vaccine mNEXSPIKE violates its mRNA vaccine design patent.
President Trump announced that Novartis CEO met with him at the White House and said the Swiss drugmaker is building 11 U.S. plants following tariff policies. Novartis previously committed $23 billion to expand U.S. facilities.
Novartis India shares hit upper circuit after Swiss parent agreed to sell 70.68% stake to ChrysCapital-led consortium for Rs 1,445.89 crore. Meanwhile, Novartis AG shares have returned 35.5% over one year, trading at CHF126.46.
The FDA has accepted for Priority Review Regeneron's biologics license application for garetosmab to treat adults with fibrodysplasia ossificans progressiva, with a target action date of August 2026.
Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.
NEXT Life Sciences has advanced two male birth control options into Phase II clinical trials: Plan A™, a long-acting reversible system, and NLS-133, a non-hormonal pill designed for on-demand or daily use.
Swiss pharmaceutical major Novartis AG has signed a definitive agreement to sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, with a mandatory open offer for an additional 26% from public shareholders.
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Scientists in Shanghai have developed DeepRare, an AI system that diagnoses rare diseases with 79% accuracy, outperforming experienced doctors in head-to-head testing. The system is now being used by clinicians at over 600 institutions worldwide.
Novartis AG agreed to sell its entire 70.68% stake in Novartis India to a consortium led by WaveRise Investments, ChrysCapital, and Two Infinity Partners for approximately ₹1,446 crore, triggering a mandatory open offer at ₹860.64 per share.
Swiss drugmaker Novartis will sell its entire 70.68% stake in its listed Indian unit to a private equity consortium for $159 million as part of broader global restructuring. Shares of Novartis India surged nearly 20% following the announcement.
Ontario has designated Kinross Gold's $5 billion Great Bear gold project for fast-track approval under its One Project, One Process framework, making it the first major miner to receive the designation. The mine near Red Lake faces opposition from Grassy Narrows over mercury contamination risks.
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
